Comparative effectiveness and safety of sarilumab vs JAK inhibitors in late- and younger-onset rheumatoid arthritis
Authors' conclusion
In routine clinical practice, SAR and JAKi support de-escalation of concomitant therapy. SAR may permit earlier MTX withdrawal without loss of disease control, with comparable GC tapering and disease activity improvement in both LORA and YORA.
Study context
- Population
- Adults with RA initiating sarilumab (SAR) or a Janus kinase inhibitors (JAKi), analysed within late-onset RA (LORA) and young-onset RA (YORA) strata
- Exposure
- SAR vs JAKi
- Outcome
- Concomitant MTX and GC tapering
- Follow-up
- 12 months
Methodological detailspropensity-score matched within LORA and YORA strata, sensitivity analyses in matched cohorts
- Propensity-score matched within LORA and YORA strata
- Sensitivity analyses in matched cohorts
Main finding
As reported in the abstract
12 months
- Both SAR and JAKi associated with progressive tapering of concomitant MTX and glucocorticoid (GC) during follow-up
- SAR associated with higher frequency of MTX discontinuation vs JAKi
- GC discontinuation and Clinical Disease Activity Index (CDAI) improvement broadly similar between treatments across age strata and MTX subgroups
- Findings consistent after propensity score matching (PSM) and in sensitivity analyses within both LORA and YORA
Observational data: associations, not effects.
Original publication
Comparative effectiveness and safety of sarilumab vs JAK inhibitors in late- and younger-onset rheumatoid arthritis. Rheumatology (Oxford). Published 8 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →